VAXESS HONORED IN 2023 BOSTINNO FIRE AWARDS

Vaxess recognized as one of Boston’s most promising biotech companies

CAMBRIDGE, Mass., October 12, 2023 — Vaxess Technologies, Inc, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, today announced that it has been recognized as a leading biotech company in BostInno’s 2023 Fire Awards, Boston’s premier awards showcase highlighting the startups, growing companies, and people that have had a banner year within the local ecosystem.

“This year’s BostInno Fire honorees represent some of the most innovative and exciting growth companies in Greater Boston,” said Carolyn Jones, market president & publisher, Boston Business Journal, BostInno. “Their work and commitment to success is a key part of the ecosystem that is Boston business. We look forward to celebrating their success and future growth.”

Vaxess’s recognition in the BostInno Fire Awards comes during a time of significant growth for the company. In September 2023, Vaxess announced an additional $9 million in financing, bringing the company’s total equity and non-dilutive funding to more than $80 million.  In August 2023, Vaxess announced that it is collaborating with AstraZeneca for the evaluation of an RNA-based pandemic influenza prototype vaccine in patch format. In June, Vaxess announced the results from the completion of its MIMIX-Flu vaccine patch phase 1 trial, with 180-day data showing the influenza vaccine patch elicited strong immune responses and was well-tolerated amongst volunteers. This year, the company also announced mRNA stability results from tests assessing the potential for room-temperature storage, and hired former Sanofi executive Steve Bende as the company’s chief strategy officer.

“2023 has been an incredibly important year for Vaxess, where our company has taken a number of significant steps towards commercialization,” said Michael Schrader, CEO and cofounder of Vaxess. “Our team is developing the only vaccine patch featuring dissolvable, sustained-release micro tips that can ‘mimic’ the pace of natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response. We look forward to bringing our first patches to market in the coming years, and are honored to receive this recognition from BostInno and The Boston Business Journal.” 

Read more about all of the 2023 BostInno Fire Awards recipients in the article, “Meet the BostInno 2023 Fire Awards honorees.”

About Vaxess Technologies

Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness while improving tolerability. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.

Vaxess has raised grant and venture capital funding from groups such as RA Capital Management, The Engine, BARDA, DARPA, NIH, NSF and the Gates Foundation. For more information, please visit the company website at www.vaxess.com or send additional inquiries to contact@vaxess.com.